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  “Y
ou already know how it ends 
when you are born”, my 
mother said in sorrow after 
my father died. And she is not even 
medically qualiﬁ  ed. Should we extend 
this common wisdom on the realities 
of old age towards the development of 
dementia? In other words, is dementia 
a curse that is inescapably linked to old 
age? 
    A New Study on Dementia before 
Death
    In a new study in   PLoS Medicine  , Carol 
Brayne and colleagues show that 
in a large population sample, the 
prevalence of dementia and severe 
cognitive impairment in the year before 
death rises steeply with age [1]. The 
researchers found that the prevalence 
of dementia in the year before death is 
up to 40%–60% in those over 90 years 
of age. They also found that nearly 
80% of those dying over 95 years of age 
suffered from moderate or more severe 
cognitive impairment. 
    The researchers examined whether 
higher levels of education and higher 
social class (proxies for a healthy 
lifestyle, e.g., taking exercise and not 
smoking) protected people from 
dementia by the time they died. While 
they did ﬁ  nd such a protective effect, 
the size of this effect was small: higher 
social class reduced the risk of dying 
with dementia by only 2%, and higher 
levels of education reduced the risk by 
only 7%. 
    Policy and Clinical Implications
    These ﬁ  gures are important and 
sobering for policy makers and for 
those who believe that dementia is 
preventable. It is difﬁ  cult to envisage 
preventive measures that would 
effectively counteract the profound 
effects of increasing age on the risk 
of dementia. As populations age, the 
burden of dementia will increase, 
and societies should be prepared for 
large numbers of elderly patients 
with dementia. Wishful thinking on 
prevention of dementia should not 
defer from the societal investments 
that are required for providing high 
quality care for these patients. That is 
an important message for policy makers 
and health-care workers alike. 
    While acknowledging both the 
methodological rigor of Brayne and 
colleagues’ analysis and the sobering 
nature of their data, it is important to 
note that their dataset does allow for 
slightly more hopeful interpretations. 
First, the authors’ strong emphasis on 
the large proportion of patients with 
dementia   at the time of death   must not 
let us forget about the importance 
of the age of onset or the duration 
of dementia. Their ﬁ  gures do not 
preclude the possibility that substantial 
gains might be made by delaying the 
onset of dementia, shortening the 
period with dementia, or both (Figure 
1). Such scenarios, which would not 
change the total number of patients 
suffering from dementia in the period 
before death, could yield enormous 
beneﬁ  ts in terms of alleviating suffering 
at younger ages and reducing the 
burden for families and other informal 
caregivers. 
    Second, the observational 
nature of the present study limits 
its interpretation in terms of cause 
and effects, especially with respect 
to the small effects of potential 
protective factors. The important 
role of cardiovascular risk factors for 
dementia and more speciﬁ  cally for 
Alzheimer disease has been recognized 
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  Figure 1.   Curves Depicting Severity of Dementia Depending on Age
      The solid line gives an estimate of a present individual trajectory. Broken lines illustrate the 
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for almost ten years [2]. This has 
fuelled the hope that at least some 
components of dementia may be 
amenable to preventive measures. Both 
observational and trial data suggest 
that treatment of hypertension does 
indeed protect against dementia, and 
the same may hold for interventions 
directed against obesity, smoking, lack 
of exercise, and glucose intolerance 
[3–10]. 
    As acknowledged by Brayne and 
colleagues, stratiﬁ  cation according to 
educational levels and social class—as 
proxies for the level of cardiovascular 
prevention—is not very strong. 
Physical ﬁ  tness, body weight, smoking 
behaviour, blood pressure, and glucose 
intolerance might have been better 
indicators, but even then observational 
studies like theirs, which can be biased 
by confounding factors, may fail 
to deﬁ  ne the potential for vascular 
prevention of dementia. 
    The Need for Randomised 
Controlled Trials
    Only properly designed randomised 
controlled trials of sufﬁ  cient power 
and sufﬁ  ciently long follow up can 
convincingly deﬁ  ne the window 
of opportunity for prevention of 
dementia. Such studies, which will be a 
major undertaking, can also document 
the precise effects of risks that may 
compete with the onset of dementia. 
Delaying the onset of dementia by, say, 
six to eight years may unmask other 
diseases in the elderly such as ischemic 
heart disease or cancer, which would 
have gone undetected if the dementia 
had not been delayed. The effects 
of these competing risks on survival 
may eventually determine if delaying 
the onset of dementia may ultimately 
result in prevention of dementia 
(Figure 1). 
    Individuals who develop dementia at 
the age of 75 or 85 years may differ in 
more respects than just the tendency 
to develop dementia. Therefore, in 
the absence of randomisation and 
without an intervention that protects 
individuals who would have developed 
dementia at a given age, observational 
studies can never precisely deﬁ  ne the 
effects of risks that may compete with 
the onset of dementia. 
    Direct studies of the beneﬁ  cial and 
adverse effects of preventive measures 
are required irrespective of their target, 
being either ß-amyloid accumulation in 
the brain or vascular brain damage. At 
least one such study is now under way 
(“Prevention of dementia by intensive 
vascular care [pre-DIVA]”, ISRCTN 
#29711771). Because of the long 
follow up that is required in studies of 
primary prevention, it will be several 
years before we will know if the one-way 
funnel leading towards nursing home 
placement can be turned into a freeway 
leading to a life free from dementia at 
old age.   
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